NPS wins thumbs up from US FDA gastro panel for Gattex
This article was originally published in Scrip
Executive Summary
After hearing the desperate pleas from several patients with short-bowel syndrome (SBS) calling for the approval of new medicines to treat their condition, a US FDA advisory panel on 16 October backed NPS Pharmaceuticals' Gattex (teduglutide) – voting unanimously that the experimental medicine's benefits outweigh its potential risks of colon polyp and tumor growth, gastrointestinal obstruction and biliary and pancreatic disorders.